ETON Relaunches HEMANGEOL via Anovo Specialty Pharmacy

Eton Pharmaceuticals, Inc. announced the relaunch of HEMANGEOL®, the only FDA-approved treatment for proliferating infantile hemangioma. The product is now exclusively available through Anovo Specialty Pharmacy to streamline access and therapy initiation. Eton has also integrated its full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs, aiming to ensure timely treatment for the estimated 5,000-10,000 infants annually affected by this time-sensitive rare disease.